Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment | Zendy

Edward Gane | Zendy; Eric Lawitz | Zendy; David Pugatch | Zendy; George Papatheodoridis | Zendy; Norbert Bräu | Zendy; Ashley Brown | Zendy; Stanislas Pol | Zendy; Vincent Leroy | Zendy; Marcello Persico | Zendy; Christophe Moreno | Zendy; Massimo Colombo | Zendy; Eric M. Yoshida | Zendy; David R. Nelson | Zendy; Christine A. Collins | Zendy; Lei Yang | Zendy; Matthew P. Kosloski | Zendy; Federico Mensa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment

Author(s) -

Edward Gane,

Eric Lawitz,

David Pugatch,

George Papatheodoridis,

Norbert Bräu,

Ashley Brown,

Stanislas Pol,

Vincent Leroy,

Marcello Persico,

Christophe Moreno,

Massimo Colombo,

Eric M. Yoshida,

David R. Nelson,

Christine A. Collins,

Lei Yang,

Matthew P. Kosloski,

Federico Mensa

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1704053

Subject(s) - medicine , kidney disease , disease , hepatitis c virus , chronic hepatitis , chronic infection , chronic renal disease , gastroenterology , immunology , virus , immune system

Chronic hepatitis C virus (HCV) infection is more prevalent among patients who have chronic kidney disease than among those who do not have the disease. Patients with chronic kidney disease who also have HCV infection are at higher risk for progression to end-stage renal disease than those who have chronic kidney disease without HCV infection. Patients with both HCV infection and advanced chronic kidney disease have limited treatment options.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research